Published in Cancer Res on July 20, 2010
MicroRNAs in stress signaling and human disease. Cell (2012) 6.93
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol (2011) 2.95
Evolution of microRNA diversity and regulation in animals. Nat Rev Genet (2011) 2.92
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (2011) 1.99
Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res (2011) 1.74
Retracted Gene-gene interaction network analysis of ovarian cancer using TCGA data. J Ovarian Res (2013) 1.40
Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A (2011) 1.28
SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther (2012) 1.18
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene (2011) 1.12
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat (2010) 1.08
SomamiR: a database for somatic mutations impacting microRNA function in cancer. Nucleic Acids Res (2012) 1.08
A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med (2012) 1.04
Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol Med (2011) 1.03
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer (2012) 1.01
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally. Front Genet (2012) 0.99
Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle (2014) 0.98
The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS One (2012) 0.95
MicroRNA 135 regulates HOXA10 expression in endometriosis. J Clin Endocrinol Metab (2011) 0.95
MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2011) 0.94
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene (2010) 0.92
MicroRNA binding site polymorphisms as biomarkers in cancer management and research. Pharmgenomics Pers Med (2014) 0.91
miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget (2015) 0.90
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res (2014) 0.88
The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. PLoS One (2014) 0.88
SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. Crit Rev Oncog (2013) 0.86
Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle (2015) 0.86
Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis (2012) 0.85
Non-coding RNAs as theranostics in human cancers. J Cell Biochem (2012) 0.85
Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol (2014) 0.84
The impact of 3'UTR variants on differential expression of candidate cancer susceptibility genes. PLoS One (2013) 0.84
Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. Oncotarget (2014) 0.83
The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. Onco Targets Ther (2014) 0.83
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. Am J Cancer Res (2012) 0.83
The role of microRNA in castration-resistant prostate cancer. Urol Oncol (2014) 0.82
MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS One (2012) 0.82
Activation of KRAS promotes the mesenchymal features of basal-type breast cancer. Exp Mol Med (2015) 0.81
MicroRNA-mediated regulation of KRAS in cancer. J Hematol Oncol (2014) 0.80
Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. Cancer Med (2014) 0.79
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene (2014) 0.78
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol (2015) 0.77
A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population. J Cancer Res Clin Oncol (2016) 0.77
Childhood cancer: an emerging public health issue in China. Ann Transl Med (2015) 0.75
Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study. Onco Targets Ther (2016) 0.75
MicroRNA Profile of Granulosa Cells after Ovarian Stimulation Differs According to Maturity of Retrieved Oocytes. Geburtshilfe Frauenheilkd (2016) 0.75
The KRAS-Variant Genetic Test As a Marker of Increased Risk of Ovarian Cancer. Rev Obstet Gynecol (2010) 0.75
Evaluation of KRAS Gene Expression and LCS6 Variant in Genomic and Cell-Free DNA of Iranian Women With Endometriosis. Reprod Sci (2014) 0.75
Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing" Clin Cancer Res (2011) 0.75
E2F1 somatic mutation within miRNA target site impairs gene regulation in colorectal cancer. PLoS One (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Common genetic variation and human traits. N Engl J Med (2009) 21.03
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
Genomewide association studies and human disease. N Engl J Med (2009) 9.05
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
Genomewide association studies--illuminating biologic pathways. N Engl J Med (2009) 8.83
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res (2008) 5.05
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat (2009) 2.60
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res (2007) 2.45
A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis (2009) 2.28
Modulated microRNA expression during adult lifespan in Caenorhabditis elegans. Aging Cell (2006) 2.14
MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Cell Cycle (2008) 1.74
Risk prediction models for familial breast cancer. Future Oncol (2006) 1.68
Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol (2009) 1.54
Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med (1997) 1.44
PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.37
Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis (2009) 1.25
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer (2009) 1.23
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer (2009) 1.08
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol (2008) 12.35
Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science (2010) 9.78
The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res (2007) 9.32
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3'UTR. Genes Dev (2004) 8.42
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Ambra1 regulates autophagy and development of the nervous system. Nature (2007) 6.94
The C elegans hunchback homolog, hbl-1, controls temporal patterning and is a probable microRNA target. Dev Cell (2003) 6.74
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
The let-7 family of microRNAs. Trends Cell Biol (2008) 6.24
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature (2010) 5.73
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol (2006) 5.09
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res (2008) 5.05
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Laparotomy versus peritoneal drainage for necrotizing enterocolitis and perforation. N Engl J Med (2006) 4.60
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
let-7 microRNAs in development, stem cells and cancer. Trends Mol Med (2008) 4.29
The time of appearance of the C. elegans let-7 microRNA is transcriptionally controlled utilizing a temporal regulatory element in its promoter. Dev Biol (2003) 3.92
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res (2007) 3.68
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 3.60
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell (2013) 3.27
Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A (2005) 3.22
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst (2013) 3.15
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet (2002) 3.04
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Micro-RNAs: small is plentiful. J Cell Biol (2002) 2.95
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol (2011) 2.95
Physicians' weight loss counseling in two public hospital primary care clinics. Acad Med (2004) 2.94
Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell (2003) 2.90
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Dev Cell (2005) 2.81
Dynamic expression of small non-coding RNAs, including novel microRNAs and piRNAs/21U-RNAs, during Caenorhabditis elegans development. Genome Biol (2009) 2.81
microRNAs and cancer: an overview. Cell Cycle (2008) 2.80
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
Randomized controlled trial of aerobic exercise on insulin and insulin-like growth factors in breast cancer survivors: the Yale Exercise and Survivorship study. Cancer Epidemiol Biomarkers Prev (2009) 2.73
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res (2009) 2.51
Focus on epithelial ovarian cancer. Cancer Cell (2004) 2.47
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res (2007) 2.45
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Architecture of a validated microRNA::target interaction. Chem Biol (2004) 2.36
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Perivascular epithelioid cell tumor (PEComa) of the uterine cervix associated with intraabdominal "PEComatosis": A clinicopathological study with comparative genomic hybridization analysis. World J Surg Oncol (2004) 2.33
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther (2003) 2.27
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res (2008) 2.24
The evolution of animal microRNA function. Curr Opin Genet Dev (2007) 2.22
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Molecular markers and death from prostate cancer. Ann Intern Med (2009) 2.15
Reciprocal expression of lin-41 and the microRNAs let-7 and mir-125 during mouse embryogenesis. Dev Dyn (2005) 2.14
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res (2012) 2.13
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med (2005) 2.06
IGF-I and breast cancer: a meta-analysis. Int J Cancer (2004) 2.03
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01